BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Medicine by Design - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Medicine by Design
X-ORIGINAL-URL:https://mbd.ccrm.ca
X-WR-CALDESC:Events for Medicine by Design
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250508T150000
DTEND;TZID=America/Toronto:20250508T170000
DTSTAMP:20260405T162844
CREATED:20250325T184952Z
LAST-MODIFIED:20250403T161618Z
UID:35227-1746716400-1746723600@mbd.ccrm.ca
SUMMARY:Building a Biotech Venture Pitch Competition
DESCRIPTION:Register now\n \n  \nJoin us in-person for the Building a Biotech Venture Pitch Competition\, where the next generation of regenerative and precision medicine innovators will showcase their entrepreneurial vision. \nSix trainee-led teams from the University of Toronto and its affiliated hospitals will pitch their cutting-edge ventures to an expert panel of judges. The winning team will receive $25\,000 in research funding to propel their technology toward real-world impact. \nThis year\, the program is led by the PRiME Next-Generation Precision Medicine in close partnership with Medicine by Design\, Health Innovation Hub (H2i) and Talk Boutique. \nOver the past months\, teams have worked with mentors to advance early-stage company concepts based on their research and have participated in a series of workshops to develop their business cases. \nThis competition represents the culmination of their journey\, where ground-breaking research meets commercialization. \nCome support these up-and-coming entrepreneurs as they take the stage to drive the future of biotechnology! \n  \nMeet the Finalist Teams\n\nA2O\nReprogramming for brain recovery \nMany central nervous system diseases are characterized by a loss of oligodendrocytes\, the cells that enable fast and efficient communication in the brain\, as well as dysfunction of astrocytes. A2O has developed a platform gene therapy technology to generate new oligodendrocytes by reprogramming these dysfunctional astrocytes – a two birds with one stone approach to brain repair. \nTeam members: Maryam Faiz\, Justine Bajohr \n\nBoutIQ Solutions Inc. \nBoutIQ Solutions Inc. leverages AI/ML-driven optimization to revolutionize cell culture media. Our cutting-edge approach enables the rapid development of complex\, custom formulations. We are pioneering next-generation\, chemically defined media that enhances physiological function and maturity\, unlocking new possibilities for disease modeling\, drug discovery\, and cell therapy. BoutIQ Solutions is redefining media innovation for the future of regenerative medicine. \nTeam members: Julie Audet\, Craig Simmons\, Neal Callaghan\, Alice Feng\, Doris Adao\, Heta Lad \n\nChase Biotherapeutics\nBreaking barriers to advance tissue regeneration \nChase Biotherapeutics is pioneering a breakthrough therapy to improve the quality of life of stroke and spinal cord injury survivors. With no viable treatments for over 12 million patients worldwide\, our disruptive technology enables the precise and localized promotion of neurorepair. Proven safe and effective in preclinical studies\, we are now advancing toward clinical trials with expert collaborators\, addressing a critical unmet need with a truly disease-modifying solution. \nTeam Members: Molly Shoichet\, Nitzan Letko Khait\, Quinton Sirianni\, Elisa Guo\, David Li \n\nLinker\nThe missing lnc for regenerative medicine \nLinker mined the dark transcriptome of humans to re-engineer long non-coding RNA (lncRNA) molecules into therapeutic products that treat inflammation associated with atherothrombotic cardiovascular disease\, which addresses a significant and underserved global clinical need. \nTeam members: Omar F. Khan\, Janice Pang \n\nPI16 Biosciences\nPioneering regenerative medicine-based solutions for skin vitality. \nOur vision at PI16 Biosciences is to harness the potential of regenerative fibroblasts to treat skin conditions with clinical grade skincare formulations that prevent infection and promote vitality. \nTeam members: Matthew Buechler\, Anthony Altieri\, Maye Cheng\, Erika McCartney\, Jia Du\, Yein Chung \n\nZearUp\nPutting an End to Low Blood Sugar: No Pill\, no Pain\, just a Patch! \nZearUp is a team of UofT pharmaceutical scientists dedicated to translating their diabetes research technology into a first-in-class clinical solution for hypoglycemia prevention in insulin-dependent individuals. Their patented ‘smart’ microgel formulation embedded within a biocompatible\, user-friendly microneedle patch is designed to raise blood sugar only when needed. Eliminating dependence on glucose monitoring and hypoglycemia rescue solutions (e.g.\, glucose pills/juice\, glucagon injections/inhalers)\, ZearUp’s patch offers unparalleled peace-of-mind\, transformative to diabetes management. \nTeam members: Xiao Yu (Shirley) Wu\, Jackie Fule Liu\, Brian Lu\, Jamie Lugtu-Pe
URL:https://mbd.ccrm.ca/event/pitch-comp-biotech-venture/
LOCATION:Myhal Centre for Engineering Innovation and Entrepreneurship\, Room 150\, 55 St George St\, Toronto\, Ontario\, M5S 0C9\, Canada
CATEGORIES:Co-hosted Events
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250312T120000
DTEND;TZID=America/Toronto:20250312T130000
DTSTAMP:20260405T162844
CREATED:20250213T143125Z
LAST-MODIFIED:20250220T145524Z
UID:35156-1741780800-1741784400@mbd.ccrm.ca
SUMMARY:Careers Beyond Academia
DESCRIPTION:What are you doing after you graduate? This is one of the biggest questions facing trainees in the life sciences. Stem Cell Network and Medicine by Design have partnered to host Careers Beyond Academia\, a virtual career seminar series that will profile a wide variety of different careers available to trainees who hold a degree in the life sciences. The goal of the series is to help trainees understand the different careers available outside of academia\, the skills required for certain positions\, and some of the daily functions of those positions. \nThis session will focus on medical affairs and feature the following speakers: \nMichelle Francisco\, MSc \nMedical Excellence and Operations Manager\, Astellas Pharma \nBryan Tennant CD\, PhD \nScientific Director\, GSK Canada \nREGISTER HERE
URL:https://mbd.ccrm.ca/event/careers-beyond-academia-5/
LOCATION:Online
CATEGORIES:Career Speaker Series,Co-hosted Events
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20250212T120000
DTEND;TZID=America/Toronto:20250212T130000
DTSTAMP:20260405T162844
CREATED:20250122T184931Z
LAST-MODIFIED:20250122T190458Z
UID:35114-1739361600-1739365200@mbd.ccrm.ca
SUMMARY:Careers Beyond Academia
DESCRIPTION:What are you doing after you graduate? This is one of the biggest questions facing trainees in the life sciences. Stem Cell Network and Medicine by Design have partnered to host Careers Beyond Academia\, a virtual career seminar series that will profile a wide variety of different careers available to trainees who hold a degree in the life sciences. The goal of the series is to help trainees understand the different careers available outside of academia\, the skills required for certain positions\, and some of the daily functions of those positions. \nThis session will focus on regulatory affairs and feature the following speakers: \nZoe Anderson-Jenkins\nAssociate Director – Regulatory CMC\nBlueRock Therapeutics \nTracy Porter\nAssociate Director\, Regulatory Strategy\,\nVertex Pharmaceuticals \nLearn more and register
URL:https://mbd.ccrm.ca/event/careers-beyond-academia-4/
LOCATION:Online
CATEGORIES:Career Speaker Series,Co-hosted Events
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20240327T150000
DTEND;TZID=America/Toronto:20240327T170000
DTSTAMP:20260405T162844
CREATED:20240229T161928Z
LAST-MODIFIED:20240322T152245Z
UID:33476-1711551600-1711558800@mbd.ccrm.ca
SUMMARY:Pitch Competition: Building a Biotech Venture program
DESCRIPTION:Join us in-person for the Building a Biotech Venture Pitch Competition to learn how the next generation of regenerative and precision medicine researchers are preparing to translate their discoveries toward impact. \nRegister here\nWatch as six trainee-led teams from the University of Toronto and its affiliated hospitals pitch their ventures to an expert panel of judges. The winning team will receive $25\,000\, and the second-place team will receive $10\,000 in research funding to advance their product concept. \nThe competition is the culmination of Medicine by Design’s Building a Biotech Venture program\, offered in partnership with the Precision Medicine Initiative (PRiME)\, Health Innovation Hub (H2i) and Talk Boutique. Over the past several months\, teams have worked with mentors to advance early-stage company concepts based on their research and have participated in a series of workshops to develop their business cases. \nCome cheer on these up-and-coming entrepreneurs as they showcase their innovative technologies. \nLocation: \nWilliam Doo Auditorium \n45 Willcocks St\, Toronto\, ON M5S 2H3 \n\n\nMeet the judges\nElla Korets-SmithMathew Platt Robin QuirkSuman Rao Ella Korets-Smith Chief Strategy Officer and Co-Founder\, Virica Biotech \nElla is an entrepreneur and business development executive for over 15 years. She has a strong track record of deals\, working with companies such as IMV Inc.\, Nordion Inc\, and Antibe Therapeutics Inc\, driving fundraising and liquidity events. In roles of increasing responsibility\, she has lead successful marketing and business development programs resulting in annual sales of over $50M. Ms. Korets-Smith has an M.Sc. in Medical Genetics from the University of Toronto and an M.B.A. from Dalhousie University. \nMathew Platt  Global Head of Venture Recruitment\, Creative Destruction Lab\nMathew is an academic by training who received his PhD in Human Health from the University of Guelph in 2019. He launched his post-academic career in deep tech startups as a Health Venture Manager at the Creative Destruction Lab (CDL) in February of 2020. In his time at CDL-Toronto\, Mathew reviewed over 500 health startup applications to the program\, worked directly with 35 health ventures spanning devices to diagnostics to drug discovery/development\, led their Health-Therapeutics stream in the fall of 2021 as a Senior Venture Manager\, and helped launch CDL-Advanced Therapies and CDL-Biomedical Engineering in the spring of 2022 as Toronto’s Associate Director of Health Streams. \nRobin Quirk Vice President Technology Sourcing & Venture Development\, CCRM\nRobin has over 20 years of experience working with regenerative medicine start-up companies. He started his career as an industry-trained pharmacist before moving into tissue engineering research. Robin joined CCRM to support the commercial development of early-stage ideas. He leads the team responsible for identifying and developing promising technologies and nurturing them to the company creation stage by strategically leveraging CCRM’s expertise and infrastructure. \nSuman Rao  Senior Associate\, Lumira Ventures \n                                                                                     Suman joined Lumira in 2021 as an Associate and focuses on conducting scientific and technical diligence of investment opportunities.  Prior to joining Lumira Ventures\, Suman worked in healthcare consulting at L.E.K. Consulting in Boston as a Life Sciences Specialist. During her time at L.E.K.\, she provided strategic advice on growth opportunities\, pipeline expansion\, potential M&A partnerships and financial modeling. Before joining L.E.K.\, Suman spent 4 years doing a Postdoctoral Fellowship at Harvard Medical School and Dana Farber Cancer Institute. During this time\, she worked with a multidisciplinary team to develop therapies to treat advanced cancers.   \n\nMeet the teams\n\nCHI Diagnostics\nThe problem is inflammation.\nAt CHI Diagnostics\, we have developed a blood test that can revolutionize post-transplant care by accurately detecting genetic markers associated with inflammation and identifying which patients are at risk of complications. This empowers us to offer personalized healthcare interventions\, minimizing invasive tests for low-risk individuals and ensuring proactive measures for those at higher risk\, ultimately optimizing post-transplant outcomes. \nTeam members: Tafsia Hussain\, Filio Billia\, John Dick\, Sagi Abelson\, Fernando Luis Scolari\, Jessie Medeiros\, Darshan H. Brahmbhatt\, Gary Bader \n\nHelixir\nEnhancing the physicians’ MR eyes.\nHelixir will use stem cell therapies to treat heart attack to demonstrate that regenerative therapies need the complement of our proprietary delivery technology to enable improved accuracy and increased therapeutic retention. This will then open the door for more minimally invasive regenerative therapies that require our pinpoint treatment delivery system. \nTeam members: Daniel Djayakarsana\, Jaykumar Patel\, Moses Cook \n\nNorthMiRs\, Inc.\nDeveloping nanotechnology-enables gene therapies to address the underlying immune dysregulation of sepsis.\nSepsis is the most common cause of death in critically ill patients\, doctors have to rely on supportive care for these patients as there are no specific treatments addressing the underlying immune dysregulation of the condition. NorthMiRs is changing this standard of care by developing a library of microRNA-based therapies that treats both systemic inflammation and organ-specific dysfunctions to ultimately improve patient outcomes\, free up space in the ICU\, and reduce the financial burden on the health system. \nTeam members: Samantha McWhirter\, Logan Zettle\, Chirag Vaswani\, Amin Ektesabi \n\nRe:Pair Genomics\nRepairing the “cures”.\nWe’ve developed AI software to design compact GPS DNAs for gene therapy to make it safe and increase product success in the clinic. What traditionally takes scientists 3-6 months can now be generated within a day. Our innovation holds significant promise for biotech and pharmaceutical firms engaged in gene therapy research and development. \nTeam members: Luca Hategan\, Yosuke Niibori\, Shiron Lee\, Swapna Prakash \n\nTwenty-nine Therapeutics\nHarnessing the power of the copper atom (element 29) to diagnose and treat metastatic disease.\nProject Twenty Nine Therapeutics includes the exploration of a promising radiopharmaceutical candidate\, Copper 67 (Cu-67)\, including its various nanomedicine applications. Cu-67 usage is novel and holds potential in theranostics and diagnostic imaging. The project Twenty Nine Therapeutics team is proposing a theranostic pairing of Copper 64 and Copper 67\, making this the first combination of these two isotopes in a nanoparticle. The isotope also has unexplored promise in the treatment of various cancers\, particularly those that have metastasized to the peritoneal lining. The team is exploring ways to firstly\, manufacture and safely ship Cu-67 and secondly\, examining its various therapeutic applications. \nTeam members: Michael Valic\, Gang Zheng \n\nVrit\nA macroporous collagen particle (MCP) based bioink and handheld bioprinter for treating full thickness skin defects.\nAt Vrit\, we’re pioneering a future where autografts are no longer necessary for surgeries. Our handheld bioprinter\, part of our broader biomaterials initiative\, empowers surgeons to provide advanced care to patients by eliminating the reliance on traditional invasive techniques. \nTeam members: Sushant Singh\, Zhenglin Lu\, Michael Li Diao
URL:https://mbd.ccrm.ca/event/pitch-competition-building-a-biotech-venture-program-2024-2/
LOCATION:William Doo Auditorium\, 45 Willcocks St\, Toronto\, Ontario\, M5S 2H3\, Canada
CATEGORIES:Co-hosted Events
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220609T130000
DTEND;TZID=America/Toronto:20220609T150000
DTSTAMP:20260405T162844
CREATED:20220509T192249Z
LAST-MODIFIED:20220512T104931Z
UID:17164-1654779600-1654786800@mbd.ccrm.ca
SUMMARY:Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials
DESCRIPTION:  \nJoin us for Spotlight on Clinical Translation: Making the leap from the lab bench to Phase I Clinical Trials\, hosted by The Stem Cell Network and Medicine by Design. \nThis workshop will provide investigators and trainees with a basic understanding of the clinical pipeline\, from essential pre-clinical studies to Phase I first in human trials. The invited speakers will review processes involved in clinical trial submission\, regulatory approval and product manufacturing. An interactive Q&A session will ensure participants can ask questions relevant to their research along with leveraging this opportunity to connect with clinical trial experts. \nClinical studies are a key element on the pathway of translational cell and gene therapies. It is\, therefore\, essential that principal investigators\, researchers\, trainees\, clinical research fellows and ecosystem partners working in Canada undertaking translational research have a thorough understanding of the clinical trial pipeline; focused specifically on the early phase clinical trial design processes. \nRegister now!\n\nRegistration deadline: \nAttendance at this event is limited; all those interested in participating must register by June 8\, 2022\, at 11:59 PM local time. \nView Agenda \n1:00-1:05 pm ET – Opening Remarks\nModerators: Harold Atkins and Darshan Brahmbhatt \n1:05-1:40 pm ET – Presentation by Natasha Kekre\, MD\, Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute \nPresentation title: Building the pre-CTA and CTA package for Phase I trials: Case study using CLIC CAR-T trial for relapsed/refractory CD19 positive hematologic malignancies \n1:45-2:10 pm ET – Presentation by Patrick Bedford\, MSc\, Managing Director\, weCANreg Consulting Group Inc. \nPresentation title: Leveraging a regulatory rerspective on your path to trials \n2:15-2:40 pm ET – Presentation by Linh Nguyen\, PhD\, Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre \nPresentation title: Developing a cell manufacturing process for an early phase clinical trial \n2:40-2:45 pm ET – Break \n2:45-3:00 pm ET – General Discussion/Q&A session \n3:00 pm ET – Closing Remarks \n\n\nSpeaker and Chair Details \nSPEAKERS\nPatrick BedfordNatasha KekreLinh NguyenPatrick Bedford \nPatrick Bedford\, MSc – Managing Director\, weCANreg Consulting Group Inc. \nPatrick Bedford is an experienced and certified regulatory professional who is focused on facilitating global regenerative medicine development. He founded & operates weCANreg Consulting Group Inc.\, which provides regulatory strategy\, interaction\, and submission services. Furthermore\, Patrick is VP of Regulatory & Development at Artisan Bio\, which is a CRISPR-enabled multiplex cell engineering company making precision immunotherapies. In his spare time\, he remains an active educator and contributor to regulatory policy development. \nPrior to incorporating his own company and leading regulatory strategy at Artisan Bio\, Patrick developed regulatory consulting services for a regenerative medicine Network Centre of Excellence; planned 2 Canadian CAR-T New Drug Submissions; and led teams at Health Canada responsible for developing guidance for biosimilars\, transplant material\, and cell & gene therapies. While leading these policy initiatives at Health Canada\, Patrick also supported their Therapeutic Products Classification Committee; chaired the Cells\, Tissues\, and Organs Classification Committee; and championed international harmonization initiatives. \nPatrick completed an Honours Bachelor of Health Sciences degree at the University of Western Ontario\, a Master’s degree in Bioethics and Health Law at the University of Otago\, a Regulatory Affairs Certificate from the Regulatory Affairs Professional Society\, and is pursuing his MBA at the Jack Welch Management Institute. \nNatasha Kekre \nNatasha Kekre\, MD – Hematologist\, The Ottawa Hospital Transplant and Cellular Therapy Program\, and Scientist\, Ottawa Hospital Research Institute\n \nDr. Natasha Kekre has been appointed to the Department of Medicine in the Division of Hematology\, within the Transplant and Cellular Therapy Program at The Ottawa Hospital\, effective October 2015. She is also an associate scientist within the Ottawa Hospital Research Institute and an associate professor of medicine at the University of Ottawa. She completed her Bachelor’s in Science at the University of Windsor then obtained her medical degree from the University of Ottawa. She then trained at the University of Ottawa in Internal Medicine and Hematology. She went on to do a fellowship in stem cell transplantation at Dana Farber Cancer Institute in Boston\, MA with a Masters in Public Health from Harvard University. \nHer research is focused on developing early phase clinical trials and moving home grown therapeutic strategies into patients. She collaborates with a number of local investigators and scientists in Ottawa\, studying hematologic malignancies and blood and marrow transplant recipients more specifically. She collaborates with scientists and physicians across Canada to build a Canadian CAR-T cell platform (chimeric antigen receptor T cells are immune cells engineered to kill cancer cells)\, bringing this exciting new therapy to Canadian patients. Her other clinical research interests include improving transplant related outcomes and projects with an epidemiologic focus\, including but not limited to decision modeling and meta-analyses. \nShe also participates with a number of cooperative groups in North America including the Center for International Blood and Marrow Transplant Research\, the Canadian Blood and Marrow Transplant Group\, the American Society of Hematology and the American Society for Transplant and Cellular Therapy. \nLinh Nguyen \nLinh Nguyen\, PhD – Staff Scientist/Head\, Cell Manufacturing Team\, Tumor Immunotherapy Program\, Princess Margaret Cancer Centre \nDr. Linh Nguyen has led the Cell Manufacturing Team of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre since 2005. Dr. Nguyen obtained her PhD in Immunology at the University of Toronto and pursued postdoctoral studies at Harvard Medical School. Her interests include tumor immunology and immunotherapy. Her team has manufactured cell and gene therapy products for clinical trials such as tumor-infiltrating lymphocytes (TILs)\, dendritic cells and T cell receptor gene-engineered T cells. The team’s activities also include quality assurance\, quality control\, and preparation of regulatory submissions. \n \nCHAIR\nHarold AtkinsDarshan H. BrahmbhattHarold Atkins \nHarold Atkins\, MD – Attending Physician\, The Ottawa Hospital Transplant and Cell Therapy Program\, and Scientist\, Ottawa Hospital Research Institute \nDr. Harry Atkins is a physician of The Ottawa Hospital Transplant and Cell Therapy Program\, an Associate Professor of Medicine at the University of Ottawa\, and a scientist in the Ottawa Hospital Research Institute’s Center for Innovative Cancer Research. \nHe received his Bachelor of Medical Science degree and Medical Degree from the University of Ottawa followed by a rotating internship year at the Victoria General Hospital in Victoria BC. Specialty training in Internal Medicine was done at the University of Ottawa. Clinical and research fellowships in Hematology\, Stem Cell Transplantation and Experimental Hematology followed at the University of Washington and at the Ontario Cancer Institute. \nHe specializes in hematopoietic stem cell transplantation and has spearheaded the use of stem cell transplantation for immune repair to treat patients with severe autoimmune diseases including multiple sclerosis\, scleroderma\, myasthenia gravis and others. The outcome of a trial using autologous hematopoietic stem cell transplantation to treat multiple sclerosis was published in the Lancet in 2016. He ran a clinical trial exploring the role of hematopoietic stem cell transplantation in preventing organ transplant rejection. He is a member of a BiocanRx funded\, pan-Canadian consortium to develop and improve the accessibility of new chimeric antigen receptor T lymphocytes for the treatment of hematological cancers. He was awarded the OHRI’s Dr. Michel Chretien Researcher of the Year in 2016\, the Till and McCulloch Award from the Stem Cell Network in 2017 and was the co-recipient of the Canadian Blood Services Lifetime Achievement Award in 2019. \nDarshan H. Brahmbhatt \nDarshan H. Brahmbhatt – MA MB BChir MPhil MRCS MRCP CCDS\, Ted Rogers Centre for Heart Function and Ajmera Transplant Centre\, University of Toronto \nDr. Darshan H. Brahmbhatt is a cardiologist who joined the UoT & TGH HF/Transplant team as a clinical fellow from London\, UK in October 2019\, having completed his doctoral research at the Royal Brompton Hospital and heart failure/device implantation training before that at Royal Papworth Hospital\, Cambridge.  His research focusses on implementation of remote monitoring and digital health solutions to assist clinicians make better decisions in managing patients with heart failure. He is currently supported by TRANSFORM-HF in his post-doctoral studies.
URL:https://mbd.ccrm.ca/event/spotlight-on-clinical-translation-making-the-leap-from-the-lab-bench-to-phase-i-clinical-trials/
LOCATION:Virtual
CATEGORIES:Co-hosted Events
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20220530T150000
DTEND;TZID=America/Toronto:20220530T170000
DTSTAMP:20260405T162844
CREATED:20220428T214037Z
LAST-MODIFIED:20220517T140217Z
UID:17094-1653922800-1653930000@mbd.ccrm.ca
SUMMARY:Pitch Competition: Building a Biotech Venture program
DESCRIPTION:  \nRegister to join the audience at the 2022 Pitch Competition!\nJoin us in-person on May 30 for the Building a Biotech Venture Pitch Competition to learn how the next generation of regenerative and precision medicine researchers are preparing to translate their discoveries toward impact. \nWatch as six trainee-led teams from the University of Toronto and its affiliated hospitals pitch their ventures to an expert panel of judges. The winning team will receive $25\,000\, and the second-place team will receive $10\,000 in research funding to advance their product concept.  \nRegister now\nThe competition is the culmination of Medicine by Design’s Building a Biotech Venture program\, offered in partnership with Precision Medicine Initiative (PRiME)\, the Health Innovation Hub (H2i) and Talk Boutique. Over the last six months\, teams have worked with mentors to advance early-stage company concepts based on their research. \nCome cheer on these up-and-coming entrepreneurs as they showcase their innovative technologies! \nNOTE: This event will be held in-person in accordance with the University of Toronto’s COVID-19 policies. Masks are required in indoor spaces where physical distancing cannot be maintained. \n\nMeet the judges\nAlberto GalassoElla Korets-Smith Angela MacDonaldRobin QuirkAlberto Galasso \n \n  \nAlberto Galasso\, PhD\nProfessor of Strategic Management\nRotman School of Management\, University of Toronto\nRead more \nElla Korets-Smith  \n\nElla Korets-Smith\, MBA\, MSc\nChief Business Officer\, Virica Biotech\nRead more \nAngela MacDonald \nAngela McDonald\, PhD\nEntrepreneur-in-Residence\, Versant Ventures\nRead more \nRobin Quirk \nRobin Quirk\, PhD\, MBA\nVice President\, Technology Sourcing & Venture Development\, CCRM\nRead more \n\n\n\nMeet the teams\nAzane Therapeutics\nDelivering the promise of RNA therapy.\nLab: Institute of Biomedical Engineering and Department of Immunology\, University of Toronto \nThis company’s product\, a delivery vehicle for mRNA-based therapies\, has the potential to make it possible for rare diseases to be treated with mRNA. The platform could also apply to regenerative medicine treatments such as stem cell reprogramming and inflammatory disorders. \n\nDTPX Therapeutics\nDeveloping immunotherapy against hibernating drug tolerant cancer cells for colorectal cancer patients.\nLab: Princess Margaret Cancer Centre\, University Health Network; and Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto. \nWhen individuals are treated for colorectal cancer with standard chemotherapy\, a cell population that’s resistant to treatment can “hibernate” and re-emerge after treatment\, causing the tumour to relapse. DTXP Therapeutics aims to create a platform that can selectively target these hibernating cells to reduce the chance of relapse\, potentially benefiting many types of cancer.\n \nGlusyn Diagnostics\nAutomated PCR-free diagnostic systems for rapid\, low-cost\, distributed usage.\nLab: Leslie Dan Faculty of Pharmacy\, University of Toronto. \nWith mastitis in dairy cows as a use-case\, this teams aims to develop automated PCR-free diagnostic systems that are shelf-stable and have low manufacturing costs.\n \nA2O\nReprogramming for recovery.\nLab: Division of Anatomy\, University of Toronto. \nA2O has developed a type of gene therapy to convert toxic brain cells back into healthy cells to treat chronic neurodegenerative disease such as multiple sclerosis and Alzheimer’s disease\, as well as acute neurological injuries such as spinal cord injury. This therapy allows for a targeted approach that can be tailored to disease type\, stage or severity.\n \nOne Drug\nEnabling next generation drugs.\nLabs: Leslie Dan Faculty of Pharmacy\, University of Toronto; Institute of Biomedical Engineering\, University of Toronto; and Department of Chemistry\, University of Toronto.\n \nDeveloping clinical point-of-care diagnostic devices that will enable clinicians and drug developers identify patients at risk of adverse drug reactions and/or suboptimal drug response based on their genetic makeup.\n \nScivance\nDeveloping therapeutics for rare disease.\nLab: Department of Chemical & Physical Sciences\, University of Toronto Mississauga \nOnly five percent of rare diseases have treatments\, and a substantial portion of these rare diseases are caused by genes called fusion oncogenes. This team is developing a proprietary algorithm and multi-disciplinary pipeline which lies at the intersection of medicinal chemistry\, structural biophysics and molecular biology\, which can help develop treatments for these disease drivers.
URL:https://mbd.ccrm.ca/event/pitch-competition-biotech-venture-2022/
LOCATION:Leslie Dan Pharmacy Building Room PB B250\, 144 College St\, Toronto\, M5S 3M2\, Canada
CATEGORIES:Co-hosted Events
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210721T130000
DTEND;TZID=America/Toronto:20210721T150000
DTSTAMP:20260405T162844
CREATED:20210625T152034Z
LAST-MODIFIED:20210720T142959Z
UID:14412-1626872400-1626879600@mbd.ccrm.ca
SUMMARY:Cell and Gene Therapies Innovations Showcase
DESCRIPTION:Join us for the Cell and Gene Therapies Innovations Showcase\, hosted by Medicine by Design and the Precision Medicine Initiative (PRiME). This two-day event will highlight cell and gene therapy strategies and enabling technologies from both academia and industry in the Canadian ecosystem. \nThis event features talks from world renowned researchers from the University of Toronto and its affiliated hospitals\, industry leaders and exceptional trainees who represent the next generation of trailblazing scientists in the field of regenerative and precision cell-based medicines. \nRegister now for session 2 \n\nDay 1 – Cell and Gene Therapies\nThursday\, July 15\, 1 p.m. to 3 p.m. – Recording Now Available\nView Day 1 Agenda \nModerator: Michael Sefton\, Executive Director\, Medicine by Design \nOpening Remarks – 1:00pm: Michael Sefton\, Executive Director\, Medicine by Design \nGroup 1 Presenters – 1:05pm-1:55pm\nShreya Shukla – Co-Founder and Director\, Research\, Notch Therapeutics\nShinichiro Ogawa – Affiliate Scientist\, McEwen Stem Cell Institute\, University Health Network\nQuinn Matthews – Master’s Student\, Keith Pardee Lab\, Leslie Dan Faculty of Pharmacy\, University of Toronto\nDaniel Wang – PhD Student\, Shana Kelley Lab\, Leslie Dan Faculty of Pharmacy\, University of Toronto \nPanel Discussion with Group 1 – 1:55pm-2:05pm: Moderated by Michael Sefton \nGroup 2 Presenters -2:10pm-2:50pm\nAndras Nagy – Founder and Director\, panCELLa\nMaryam Faiz – Assistant Professor\, Department of Surgery\, University of Toronto\nChristoph Haller – Cardiovascular Surgeon\, The Hospital for Sick Children and PhD Candidate\, Michael Laflamme Lab\, McEwen Stem Cell Institute\, University Health Network \nPanel Discussion with Group 2 – 2:50pm-3:00pm: Moderated by Michael Sefton \nClosing Remarks – 3:00pm \n\nAcademic Researchers\nMaryam\nFaizShinichiro Ogawa Christoph\nHallerQuinn\nMatthewsDaniel\nWangMaryam\nFaiz \n \nAssistant Professor\, Department of Surgery\, University of Toronto\nMaryam Faiz received her PhD from the Autonomous University of Barcelona in Spain. She trained with  Milos Pekny at the University of Goteborg in Sweden\, and then with Dr. Andras Nagy at the Lunenfeld-Tanenbaum Research Institute in Toronto. Faiz is interested in uncovering new treatments for brain injury and disease. Her lab is interested in the roles of astrocytes in the injured/diseased brain\, and how this knowledge can inform future therapeutic interventions. One exciting area of research she is currently pursuing is the direct lineage reprogramming of astrocytes to neurons and oligodendrocytes. She believes that the ability to create bespoke cell types\, at the source of injury or disease may revolutionize the next generation of CNS therapeutics. \nShinichiro Ogawa  \nAffiliate Scientist\, McEwen Stem Cell Institute\, University Health Network\n \nShinichiro Ogawa is an Affiliate Scientist at the McEwen Stem Cell Institute (MSCI) with a cross-appointment at the Multi-Organ Transplant Program at UHN and is an Assistant Professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. As a trained clinician and hepato-biliary\, liver transplant surgeon in Japan\, he is also appointed as a Professor of Surgery at the Shinshu University School of Medicine in Japan. His research work focuses on using stem cell biology to generate functional hepatocytes and cholangiocytes from human pluripotent stem cells with the long-term goal of developing targeted cell therapies for liver disease.   \n Ogawa obtained his MD at the Tokyo Medical University in 1994 and his PhD at the Shinshu University School of Medicine in 2005 in Japan. Ogawa continued his training as a postdoctoral fellow and subsequently as a Scientific Associate under Gordon Keller before starting his independent research program in April 2019.   \nSince joining the Keller laboratory\, Ogawa has made significant progress in advancing the field of liver regenerative medicine. He has successfully developed a method to generate functional liver cells—hepatocytes\, and cholangiocytes—from human pluripotent stem cells\, which is a remarkable accomplishment. In his independent research\, he will continue this outstanding trajectory by evaluating the optimal graft composition of these cells for treating different forms of liver failure in pre-clinical transplantation studies\, and further elucidate the drivers of hepatic lineage development in pluripotent stem cells. In parallel\, he will continue developing a methodology to produce an unlimited supply of human liver cells and to develop novel cell therapies for liver diseases.  \n  \nChristoph\nHaller \nCardiovascular Surgeon\, Division of Cardiovascular Surgery\, The Labatt Family Heart Centre\, The Hospital for Sick Children and PhD Candidate\, Michael Laflamme Lab\, Department of Laboratory Medicine & Pathobiology\, Institute of Biomedical Engineering\, McEwen Stem Cell Institute\, University Health Network\n \nDr. Christoph Haller graduated from Albert-Ludwigs University Freiburg\, Germany and completed his cardiac surgery training in the Department of Cardiovascular Surgery at the University Hospital Freiburg\, Germany\, and the Department of Thoracic and Cardiovascular Surgery at the University Hospital Tuebingen\, Germany. Early in his career\, he subspecialized in congenital heart surgery and completed clinical and research fellowships at the Hospital for Sick Children\, University of Toronto.   \nHis practice is focused on open heart surgery in neonates and infants and adult congenital heart disease\, covering the spectrum of congenital heart disease from single ventricle palliation to mechanical support and heart transplantation. He is leading the minimally invasive congenital heart surgery program at SickKids. Dr. Haller’s academic interests are focused on the preservation\, recovery\, and regeneration of cardiac function. He is applying stem cell therapy\, mechanical circulatory support\, and new imaging technologies in various translational fetal\, pediatric and adult research models to investigate mechanisms of heart failure and therapeutic strategies to preserve or restore function. Dr. Haller is further exploring extrauterine fetal support commonly referred to as artificial placenta to lower morbidity and mortality in extremely premature neonates and to apply innovative therapeutic approaches to this most fragile group of patients.  \n  \nQuinn\nMatthews \nMaster’s Student\, Keith Pardee Lab\, Leslie Dan Faculty of Pharmacy\, University of Toronto \nOriginally from Vancouver\, Quinn joined Professor Keith Pardee’s research group as a MSc student in 2019. He’s passionate about de-centralizing science/healthcare\, and is involved in a few projects within the lab that aim to solve real-life problems using synthetic biology.   \n  \n  \n  \nDaniel\nWang \nPhD Student\, Shana Kelley Lab\, Leslie Dan Faculty of Pharmacy\, University of Toronto \nDaniel Wang is a Connaught scholar and PhD student in the lab of Shana Kelley\, University of Toronto. His research focuses on the enabling technology for next-generation cell therapy\, including cell sorting and bioprinting. As the co-author \, he published > 30 papers that have been cited over 2\,000 times.  \n\n\n\nCompany Spotlights\nAndras Nagy - panCELLaShreya Shukla - Notch TherapeuticsAndras Nagy - panCELLa \nFounder and Director\, panCELLa\nNagy is currently a Shawn Kimel Senior Scientist at the Lunenfeld-Tanenbaum Research Institute\, Sinai Health System\, Professor in the Department of Obstetrics & Gynaecology and Institute of Medical Science at the University of Toronto and Professor at the Australian Regenerative Medicine Institute in Monash University\, Melbourne. He holds a Tier I Canada Research Chair in Stem Cells and Regeneration. He is a Fellow of the Royal Society of Canada in the Life Sciences Division of the Academy of Science\, a Foreign Member of the Hungarian Academy of Science\, an Honorary Professor at the Helsinki University\, and a Distinguished Professor at the Honk Kong University. \nDr. Nagy’s endeavours have led to unprecedented breakthroughs in developmental genetics\, mouse and human pluripotent stem cell biology (both embryonic and reprogramming-induced)\, disease modelling and cell therapy approach. His team created the first Canadian human embryonic stem cell lines in early 2000. A decade later\, they developed the first method allowing the generation of iPS cell lines without any genetic change. Their approach allowed studying the reprogramming process at multiple OMICS levels\, virtually at a daily resolution from differentiated cells to pluripotency. His current research has become increasingly translational by addressing and developing solutions for the two most significant hurdles of cell therapies: safety and allogeneic cell acceptance without the need for suppression of the recipient’s immune system. His research has been aiming to advance medicine with a focus on currently incurable degenerative diseases\, such as blindness\, diabetes\, arthritis\, spinal cord injury\, multiple sclerosis\, haemophilia\, hypoparathyroidism and others. \nShreya Shukla - Notch Therapeutics \nCo-Founder and Director\, Research\, Notch Therapeutics  \nShreya Shukla is a Co-Founder and Director of Research at Notch Therapeutics. She oversees iPSC differentiation platform development and leads the design and optimization of the T cell differentiation process. She supports senior leadership for the ideation\, technical diligence and implementation of new programs and technologies in the Notch pipeline. She also contributes to relevant intellectual property strategy and patent filings related to novel product or process developments. Previously\, Shreya worked at CCRM as a scientist/entrepreneur\, where she drove forward the creation and launch of Notch Therapeutics as a new cell therapy company incubation within CCRM. As a co-inventor\, she designed and performed proof-of-concept studies to demonstrate therapeutic utility of intellectual property from her Ph.D that was subsequently in-licensed to Notch. Shreya has a B.S. in Biomedical Engineering from Georgia Institute of Technology in U.S.A. and completed her Ph.D. in Biomedical Engineering from Dr. Peter Zandstra’s stem cell bioengineering laboratory at the University of Toronto in Canada. \n\n\nDay 2 – Enabling Technologies\nWednesday\, July 21\, 1 p.m. to 3 p.m. – Next Session\nView Day 2 Agenda \nModerator: Shana Kelley\, Director\, Precision Medicine initiative (PRiME)\, University of Toronto \nOpening Remarks – 1:00pm: Shana Kelley\, Director\, Precision Medicine initiative (PRiME)\, University of Toronto \nGroup 1 Presenters – 1:05pm-1:45pm\nMaude Dumont-Lagacé – Associate Director of R&D and Special Projects\, ExCellThera\nPenney Gilbert – Associate Professor\, Institute of Biomedical Engineering\, University of Toronto\nRony Chidiac – Postdoctoral Fellow\, Stéphane Angers Lab\, Leslie Dan Faculty of Pharmacy\, University of Toronto \nPanel Discussion with Group 1 – 1:45pm-1:55pm: Moderated by Shana Kelley \nGroup 2 Presenters – 2:00pm-2:40pm\nSam Wadsworth – Chief Scientific Officer\, Aspect Biosystems\nLiliana Attisano – Professor\, Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto\nMarie Abou Chakra – Research Associate\, Gary Bader Lab\, Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto \nPanel Discussion with Group 2 – 2:40pm-2:50pm: Moderated by Shana Kelley \nClosing Remarks – 2:50pm \n\nAcademic Researchers\nLiliana\nAttisano Penney\nGilbertMaria\nAbou Chakra Rony\nChidiac Liliana\nAttisano  \nProfessor\, Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto \nLiliana Attisano is a Professor and Interim Chair in the Dept. of Biochemistry\, with a laboratory based in the Donnelly Centre. Dr. Attisano’s lab is focused on studying the molecular events that underlie signalling cascades and elucidating how cells interpret contextual cues to control complex biological responses. Her lab uses cells\, mice and most recently human stem cell-derived organoid models to better understand how disruptions in signalling pathways underlie human disease processes including cancer and neurological disorders. \n  \nPenney\nGilbert \nAssociate Professor\, Institute of Biomedical Engineering\, University of Toronto \nPenney M. Gilbert is an Associate Professor at the University of Toronto in the Institute of Biomedical Engineering. Gilbert received her PhD from the University of Pennsylvania (2006) and conducted Postdoctoral studies at Stanford University (2007 – 2012). Her team engineers and studies three-dimensional models of human skeletal muscle and explores muscle stem cell mechanobiology with the goal of identifying signaling pathways that can be tweaked to boost the function of skeletal muscle stem cells in the body. She is recipient of an Ontario Early Researcher Award and holds a Canada Research Chair in Endogenous Repair.   \nMaria\nAbou Chakra  \nResearch Associate\, Gary Bader Lab\, Donnelly Centre for Cellular and Biomolecular Research\, University of Toronto \nMaria Abou Chakra is a trained biologist with a PhD in Computational & Mathematical Biology from McMaster University. During her graduate degree she trained in theoretical morphology in the lab of Jon Stone. She developed a mathematical model that explores both growth and form of sea urchin skeletons. After graduating she moved to Germany to work as a post-doctoral fellow at the Max Planck Institute for Evolutionary Biology. In the evolutionary theory department she was trained by Arne Traulsen in evolutionary game theory.  She developed models that capture and predict behaviors in complex social dilemmas such as Climate Change negotiations and Host parasite interactions. Currently since 2016 she has been working as research associate in the lab of Gary Bader developing 3D mathematical models that explore cell development. She is trying  to understand how cells control gene expression timing and cell fate decisions during development.  \nRony\nChidiac  \nPostdoctoral Fellow\, Stéphane Angers Lab\, Leslie Dan Faculty of Pharmacy\, University of Toronto \nI am a postdoctoral fellow in the laboratory of Dr. Stephane Angers at the Leslie Dan Faculty of Pharmacy at the University of Toronto. I hold a PhD in pathology and cell biology from the Université de Montréal. During my PhD\, I used proteomic approaches to elucidate signalling pathways activated by growth factors in endothelial cells during angiogenesis. My current research interest is to modulate Wnt pathway activity using novel antibody-based agonists selectively targeting Frizzled receptors recently developed by the Angers and Sidhu teams for regenerative medicine therapies. My main focus is to examine the therapeutic potential of our synthetic antibodies in normalizing pathological and leaky blood vessels in eye diseases. Also\, I am interested in activating Wnt pathway using selective antibodies to precisely control directed differentiation of hPSCs and cell fate specification for regenerative medicine applications. I am a member of the MbD cycle 2 teams. I was a 2019 PRiME fellowship awardee and I was recently awarded a postdoctoral fellowship award from the BrightFocus Foundation.   \n\nCompany Spotlights\nMaude Dumont-Lagacé - ExCellTheraSam Wadsworth - Aspect BiosystemsMaude Dumont-Lagacé - ExCellThera \nAssociate Director of R&D and Special Projects\, ExCellThera \nMaude Dumont-Lagacé completed a PhD in molecular biology with a specialization in immunobiology at the Université de Montréal\, Canada. She joined ExCellThera in 2018\, where she participates in clinical research focusing on UM171 expanded CB grafts. Working in close collaboration with the hematologists team leading the clinical trials at Maisonneuve-Rosemont Hospital\, she led the study of immune reconstitution in patients transplanted with UM171 expanded cord blood grafts. More recently\, she is exploring how cord blood expansion increases donor availability for different populations.  \n  \nSam Wadsworth - Aspect Biosystems \n \nChief Scientific Officer\, Aspect Biosystems \nSam Wadsworth\, Ph.D.\, Chief Scientific Officer & Co-Founder Aspect Biosystems. Sam has spent two decades driving developments in human tissue engineering. In 2013\, Sam co-founded the UBC spin-out\, Aspect Biosystems with Konrad Walus\, Simon Beyer and Tamer Mohamed. Aspect Biosystems is a biotechnology company creating bioprinted therapeutics as medicines of the future. Aspect is applying its microfluidic 3D bioprinting technology internally to develop these advanced cell therapies and partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Sam will be discussing Aspect’s proprietary bioprinting technology and will describe how it has the potential to revolutionize the field of regenerative medicine by enabling a new generation of allogeneic cell therapies.
URL:https://mbd.ccrm.ca/event/cell-and-gene-therapies-innovations-showcase/
LOCATION:Virtual
CATEGORIES:Co-hosted Events
ORGANIZER;CN="Medicine by Design":MAILTO:info.mbd@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210519T150000
DTEND;TZID=America/Toronto:20210519T170000
DTSTAMP:20260405T162844
CREATED:20210323T202553Z
LAST-MODIFIED:20210505T192900Z
UID:13286-1621436400-1621443600@mbd.ccrm.ca
SUMMARY:Pitch Competition: Building a Biotech Venture program
DESCRIPTION:Learn how the next generation of regenerative medicine researchers at the University of Toronto and its affiliated hospitals are preparing to translate their discoveries toward impact. At the Building a Biotech Venture Pitch Competition\, six trainee-led teams will pitch their regenerative medicine-related products or ventures to an expert panel of judges and compete for up to $25\,000 in research funding. \nRegister now to watch the teams compete \nThe competition is the culmination of Medicine by Design’s Building a Biotech Venture program\, offered in partnership with H2i. Over the past three months\, the program has offered workshops and mentoring to help teams advance company or product concepts based on their regenerative medicine research. The teams with the highest potential for company creation have been selected to take part in the pitch competition.  \n\nMeet the judges\nMike CookeAvi GoldfarbRobin QuirkAndrea SampsonEmily TitusMike Cooke \nMike Cooke\, PhD\, is the Co-Founder & CEO of AmacaThera. AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique\, injectable hydrogel platform technology for a wide range of medical applications. Mike co-founded the company along with renowned biomaterials scientist\, Molly Shoichet. Mike co-developed the first product for AmacaThera\, a sustained analgesic for post-operative pain\, which he pitched to both UTEST and OBIO and secured dilutive and non-dilutive seed investment. Mike has secured over C$12MM in venture capital financing for AmacaThera. Mike completed his PhD at Durham University (UK) and a post-doctoral fellowship in the Shoichet Lab at the University of Toronto. Mike is currently pursuing a Global Professional Master of Laws (GPLLM) in Business Law at the University of Toronto. \nAvi Goldfarb \nAvi Goldfarb\, PhD\, is the Rotman Chair in Artificial Intelligence and Healthcare\, and Professor of Marketing\, at the Rotman School of Management\, University of Toronto. Avi is also Chief Data Scientist at the Creative Destruction Lab where he manages the health stream\, Senior Editor at Marketing Science\, and a Research Associate at the National Bureau of Economic Research. He has published over 80 academic articles in a variety of outlets in marketing\, statistics\, law\, management\, refugee studies\, medicine\, computing\, and economics. Along with Ajay Agrawal and Joshua Gans\, Avi is the author of the book Prediction Machines: The Simple Economics of Artificial Intelligence and editor of the NBER book The Economics of Artificial Intelligence: An Agenda. Avi received his PhD in economics from Northwestern University. Robin Quirk \nRobin Quirk\, PhD\, MBA is the Director of Technology Sourcing and Venture Development at CCRM. Robin has over 20 years of experience working with regenerative medicine start-up companies. He started his career as an industry-trained pharmacist before moving into tissue engineering research. Robin joined CCRM to support the commercial development of early-stage ideas. He leads the team responsible for identifying and developing promising technologies and nurturing them to the company creation stage by strategically leveraging CCRM’s expertise and infrastructure. \nAndrea Sampson \nAndrea Sampson is Co-Founder & Executive Speaker Coach at Talk Boutique. She is a former Strategist and Consultant and has spent over 25 years working in marketing and advertising\, presenting and developing strategies for Fortune 100 companies. With a natural talent for developing compelling stories and persuasive content\, Andrea is sought after in assisting teams and executives develop their presentations or pitches. Four years ago\, Andrea’s passion for ideas led her to TEDxToronto where she volunteered initially as a Speaker Coach\, then as the Director of Programming in 2015 and the Conference Co-Chair in 2016. This voluntary role was instrumental in the creation of Talk Boutique\, a speaker management\, development and representation company. Andrea was the Co-Director of the 2017 Singularity University Canada Summit.Emily Titus \nEmily Titus\, PhD\, is Vice President\, Process Sciences at Notch Therapeutics. Previously\, she was Vice President\, Technology Advancement at CCRM\, where she built cell reprogramming\, genome engineering\, and pluripotent stem cell differentiation programs and led the formation of Notch Therapeutics as part of CCRM’s company incubation program. Emily earned a PhD from the Institute of Biomedical Engineering at the University of Toronto\, where she used a combination of laboratory and bioinformatics approaches to define and interpret gene regulatory networks controlling embryonic stem cell fate decisions. \n\n\nMeet the teams\nDandelion Biologics\nDandelion Biologics provides an advanced antibody development platform for challenging therapeutic targets. \nHDAX Therapeutics\nHDAX Therapeutics focuses on developing epigenetic-targeting treatments through designing and synthesizing the next generation of life-improving medicines to tackle unmet healthcare needs in cancer and central nervous system disorders.\n \nLaetech\nLaetech harnesses the regenerative capacity of fat to improve the clinical outcomes of cosmetic and reconstructive surgical procedures.\n \nLifeScreen\nLifeScreen is developing a new approach to personal wellness using biological age. \n\nMyoThera\nMyoThera identifies therapeutic targets to boost the impaired regenerative capacity of skeletal muscle in Duchenne muscular dystrophy patients. \n\nPancraTECH\nPancraTECH is using stem cells to generate a cellular therapy for patients with type 1 diabetes.
URL:https://mbd.ccrm.ca/event/pitch-competition-building-a-biotech-venture-program/
LOCATION:Ontario
CATEGORIES:Co-hosted Events
END:VEVENT
END:VCALENDAR